bs-3535R-RBITC [Conjugated Primary Antibody]
PLK1 Polyclonal Antibody, RBITC Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: PLK1

Immunogen Range: 201-300/603


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 5347

Swiss Prot: P53350

Source: KLH conjugated synthetic peptide derived from human PLK1

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

PLK1 (polo-like kinase 1) is a member of the serine/threonine protein kinase family, cdc5/polo subfamily. PLK1 contains two polo box domains with a predicted molecular weight of 68 kDa. PLK1 has been shown to regulate cdc2/cyclin B through phosphorylation and activation of cdc25c phosphatase. PLK1 is modified by phosphorylation at Threonine 210. PLK1 may also be required for cell division. Depletion of PLK1 results in apoptosis and deregulation of expression of PKL1 is correlated with development of many malignancies.

Conjugation: RBITC

Excitation/ Emission: 540nm/625nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 66


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Pig
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Gibori et al. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. (2018) Nat.Commun. 9:16Read more>>
  • Chen Y et al. PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/\catenin signalling pathway. J Cell Mol Med. 2020 Jul;24(13):7405-7416.Read more>>
  • Gaizhen Kuang. et al. Near-Infrared Light-Triggered Polyprodrug/siRNA Loaded Upconversion Nanoparticles for Multi-Modality Imaging and Synergistic Cancer Therapy. 2021 Jul 03Read more>>
  • Cong Lan. et al. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. EBIOMEDICINE. 2022 Aug;82:104139Read more>>